Osteopenia or Osteoprosis Clinical Trial
Official title:
Long-term Effect of Electromagnetic Field in Treatment of Patients With Osteopenia or Osteoporosis. A Randomized Placebo-controlled Trial.
Verified date | October 2020 |
Source | Umm Al-Qura University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Osteoporosis is the most prevalent metabolic bone disease. Although osteoporosis is widely considered to be much more prevalent in women approximately 39% of new osteoporotic fractures estimated to have occurred worldwide in 2000 were in men. A number of studies investigate the effect of physical therapy modalities in treatment of osteoporosis. The use of pulsed electromagnetic field (PEMF) represents an attractive alternative for osteoporosis. Previous studies suggested that pulsed electromagnetic field could be beneficial for increase bone mineral density in osteoporotic patients, but there is a lack of knowledge about the long term effect on several parameters.
Status | Completed |
Enrollment | 120 |
Est. completion date | August 25, 2020 |
Est. primary completion date | August 25, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 60 Years |
Eligibility | Inclusion Criteria: - Patients with a T-scores of = ?1.5, all patients received the same medical treatment for osteoporosis and the same average blood glucose level, sufficient ability to understand the nature and potential risks of the study. Exclusion Criteria: - Diabetes mellitus, ischemic heart disease, arrhythmia, uncontrolled thyroid disease, cardiac pacemaker, tuberculosis, neuropsychiatric disorders (dementia, cerebrovascular disease, alcohol abuse, severe depression, panic disorder, bipolar disorder, or psychosis), and malignancy. |
Country | Name | City | State |
---|---|---|---|
Saudi Arabia | Al Noor Specialized Hospital | Mecca |
Lead Sponsor | Collaborator |
---|---|
Umm Al-Qura University |
Saudi Arabia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline Bone Mineral Density at 3 months | Bone Mineral Density will assessed by the DEXA in the lumbar spine, proximal femur and forearm region in g/cm2. | Baseline and 3 months, and 6 months post-intervention | |
Primary | Change from baseline Vitamin D levels at 3 months | Vitamin D test is the most accurate way to measure how much vitamin D is in the body. Vitamin D in serum will measured as a standard procedure at the Department of Clinical Chemistry. | Baseline and 3 months, and 6 months post-intervention | |
Primary | Change from baseline Alkaline Phosphatase at 3 months | Alkaline Phosphatase will be estimated colorimetric end point and kinetic using fully automated analyzer Advia Centaur, according to enclosed pamphlet. | Baseline and 3 months, and 6 months post-intervention | |
Secondary | Change from baseline Osteocalcin at 3 months | Ostocalcin is a predictive marker for osteoprosis and bone fracture. Serum Osteocalcin will measured in serum samples using an ELISA Kits. | Baseline and 3 months, and 6 months post-intervention | |
Secondary | Change from baseline Parathyroid Hormone at 3 months | Parathyroid hormones (PTH) will measurement chemiluminescence immunoassays [QuiCkIntraOperativeTM intact PTH. The assay will performed on the Immuno- automated analyzer (DPC) at the Department of Clinical Chemistry at Um ALQURA University, Faculty of Applied Medical Science. The Roche intact-PTH test will be assayed on an Elecsys-1010 immunoassay analyzer (Roche Diagnostics) with its "Stat-function. | Baseline and 3 months, and 6 months post-intervention |